–The presentation includes new preclinical data for PM359, further demonstrating Prime Editor's ability to efficiently, reproducibly, and permanently correct mutations that cause CGD. The drug is on track to enter clinical development in 2024, with initial data expected in 2025 —
— Prime Medicine co-founder Dr. David Liu receives ASGCT Outstanding Achievement Award —
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (NASDAQ: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative gene therapies, announced today that , the company announced the following: will present preclinical data highlighting the broad potential of Prime Editing technology and supporting program advancement in its third clinical trial.rd Annual LNP Formulation and Process Development Summit (Boston, April 29-May 2, 2024). American Society for Cell and Gene Therapy 27th Annual Meeting (Baltimore, May 7-11, 2024); and TIDES USA Oligonucleotide and Peptide Therapeutics Conference (Boston, May 14-17, 2024).
“In the short time since Prime Editing was first discovered, we have evolved this technology, developed and optimized Prime Editor for programs across our core focus areas, and believe that Prime Editor is safe to use. “We have made incredible advances, including creating new delivery systems that allow us to effectively access target tissues,” said Keith Gottesdiener, MD, President and CEO of Prime Medicine. states. “This progress will be highlighted by an upcoming presentation. This presentation will highlight the first programs expected to enter clinical development, a new preclinical development of PM359 for severe and life-threatening chronic granulomatous disease (CGD). New discoveries from across our platform and early pipeline will be highlighted, including data on rare diseases that pose a threat. In addition to our presentation, we will highlight his achievements in the gene editing field, including his contributions to the discovery and advancement of prime editing, and co-founder David Liu will present his ASGCT Outstanding Achievement Award. Congratulations on winning the award. We look forward to collaborating with the scientific research community and highlighting our leadership position in the field of next-generation gene editing. ”
Details of the lecture content are as follows.
3rd Annual LNP Formulation and Process Development Summit (Boston)
American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting (Baltimore)
-
Presentation name: Development and provision of Prime Editor
-
Date Time: Tuesday, May 7, 2024, 9:45 a.m. ET
-
Presenter: Dr. Jonathan Levy
-
-
Poster name: Exon reframing with Prime Editor restores dystrophin
-
Date Time: Wednesday, May 8, 2024, 12:00 PM ET (Poster Session)
-
presenter: Dr. Michelle O'Connor
-
-
Presentation name: Development of a prime-edited CD34+ cell drug for the treatment of P47phox chronic granulomatous disease
-
Date Time: Wednesday, May 8, 2024, 5:15 PM ET
-
Presenter: Dr. Jennifer Gori
-
-
Presentation name: Off-target analysis shows favorable safety profile of prime editing
-
Date Time: Friday, May 10, 2024, 2:45 PM ET
-
Presenter: Dr. Maria Collier
-
-
Presentation name: Prime Editors precisely correct pathogenic RHO mutations and maintain photoreceptors in vivo
-
Date Time: Wednesday, May 8, 2024, 3:45 PM ET
-
Presenter: Dr. Deepak Rayon
-
TIDS USA Oligonucleotide and Peptide Therapeutics Conference (Boston)
-
workshop: Overview of genome editing
-
Date Time: Tuesday, May 14, 2024, 9:00 a.m. ET
-
Presenter: Dr. Jeffrey Husman
-
-
Presentation name: Challenges and prospects for gene editing, regulation, and delivery
-
Date Time: Tuesday, May 14, 2024, 4:15 PM ET
-
Presenter: Dr. Luis Santos
-
-
Presentation name: An RNA-based approach to achieve prime editing
-
Date Time: Thursday, May 16, 2024, 10:45 a.m. ET
-
Presenter: Dr. Seth Alexander
-
-
Presentation name: Prime Editing Guide (PEG)RNA Analysis Development
-
Date Time: Friday, May 17, 2024, 11:45 a.m. ET
-
Presenter: Dr. Yang Shankun
-
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to developing and delivering next-generation gene editing therapies to patients. The Company is deploying its proprietary Prime Editing Platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time curative gene therapies. Designed to minimize unnecessary DNA modifications and make only the right edits at the right location within a gene, Prime Editor repairs almost any type of genetic mutation and is highly effective in many different tissues and organs. , has the potential to function in cell types. Taken together, Prime Editing's versatile gene editing capabilities could open up opportunities across thousands of potential indications.
Prime Medicine currently has a diverse portfolio of investigational treatment programs organized around core focus areas: hematology and immunology, liver, lung, eye and neuromuscular. Across each core area, Prime Medicine's initial focus will be on genetic diseases with rapid and direct routes to treating patients, with high unmet diseases currently underserved using other gene editing approaches. There is no need to deal with it. Over time, we intend to take full advantage of Prime Editing's broad and diverse therapeutic potential and expand beyond the genetic diseases in our initial pipeline. This can include immune disorders, cancer, and infectious diseases, as well as genetic risk factors for common diseases that together affect millions of people. people. For more information, please visit www.primemedicine.com.
© 2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logo, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks mentioned herein are the property of their respective owners.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including implicit and express statements regarding Prime Medicine's beliefs and expectations regarding: but not limited to. PM359 has the potential to correct mutations that cause CGD. Expectations regarding the breadth and potential of Prime Editing technology. Expand Prime Editing's reach and impact beyond Prime Medicine's current core focus by expanding Prime Editing's therapeutic potential and creating value through strategic business development do. PM359 will be introduced into clinical development in 2024, with initial data expected to be obtained in 2025, and the company is expected to mature into a clinical-stage company. Prime editors could then repair genetic mutations and provide curative gene therapies for a wide range of diseases. “may”, “might”, “would”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend” words such as “will,” “believe,” “expect,” “estimate,” “seek,” “forecast,” “future,” “plan,” “potential,” “continue,” “goal,” and similar words. Although the words and expressions are intended to identify forward-looking statements, not all statements are forward-looking statements. The search statement includes these identifying words.
The forward-looking statements in this press release are based on management's current expectations and beliefs and could cause actual events or results to differ materially from those expressed or implied by the forward-looking statements. are subject to a number of risks, uncertainties and important factors. Statements contained in this press release include, but are not limited to, risks related to: uncertainties associated with filing an IND or CTA and initiating clinical trials; the approval, initiation and conduct of preclinical and IND-enabling studies and other development requirements for potential product candidates, including uncertainties associated with opening an IND and obtaining regulatory approval; risks associated with the development and optimization of new technologies, the results of preclinical studies, or clinical studies in which future results cannot be predicted in connection with future studies; the scope of protection that allows Prime Medicine to establish and maintain its intellectual property rights, including the Prime Editing technology; Prime Medicine's ability to identify and enter into future license agreements and collaborations; general economic, industry and market conditions, such as rising interest rates, inflation and adverse conditions affecting the financial services industry; These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Prime Medicine's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. I am. Further, forward-looking statements represent Prime Medicine's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Prime Medicine expressly disclaims any obligation to update any forward-looking statements as required under applicable law. No representation or warranty (express or implied) is made as to the accuracy of such forward-looking statements.
Investor contact information
Hannah Deresiewicz
Stern Investor Relations Co., Ltd.
212-362-1200
hannah.deresiewicz@sternir.com
media contact
Dan Budwick, 1AB
dan@1ABmedia.com